Concepts (64)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Interferon Type I | 1 | 2022 | 10 | 0.200 |
Why?
|
| Lupus Nephritis | 1 | 2022 | 27 | 0.190 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2021 | 7 | 0.180 |
Why?
|
| Neovascularization, Physiologic | 1 | 2021 | 25 | 0.180 |
Why?
|
| CD18 Antigens | 1 | 2020 | 2 | 0.180 |
Why?
|
| Integrins | 1 | 2020 | 13 | 0.180 |
Why?
|
| CD11b Antigen | 1 | 2020 | 16 | 0.180 |
Why?
|
| Macular Edema | 1 | 2020 | 7 | 0.170 |
Why?
|
| Up-Regulation | 1 | 2021 | 170 | 0.170 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2022 | 190 | 0.160 |
Why?
|
| DNA Repair | 1 | 2013 | 7 | 0.110 |
Why?
|
| Anthracyclines | 1 | 2013 | 17 | 0.110 |
Why?
|
| Peritonitis | 1 | 2013 | 17 | 0.110 |
Why?
|
| Lung | 1 | 2013 | 168 | 0.100 |
Why?
|
| Sepsis | 1 | 2013 | 113 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 370 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 599 | 0.070 |
Why?
|
| Animals | 3 | 2021 | 3642 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 420 | 0.060 |
Why?
|
| Mice | 2 | 2020 | 1395 | 0.050 |
Why?
|
| Antibodies, Antinuclear | 1 | 2022 | 12 | 0.050 |
Why?
|
| Toll-Like Receptors | 1 | 2022 | 17 | 0.050 |
Why?
|
| Tropomyosin | 1 | 2021 | 4 | 0.050 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2020 | 12 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2020 | 11 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2021 | 46 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2020 | 31 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2020 | 23 | 0.040 |
Why?
|
| Heart | 1 | 2021 | 63 | 0.040 |
Why?
|
| Leukocytes | 1 | 2020 | 34 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2020 | 41 | 0.040 |
Why?
|
| India | 1 | 2020 | 17 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2020 | 21 | 0.040 |
Why?
|
| Drug Implants | 1 | 2020 | 9 | 0.040 |
Why?
|
| Intravitreal Injections | 1 | 2020 | 11 | 0.040 |
Why?
|
| Visual Acuity | 1 | 2020 | 41 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 219 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2020 | 34 | 0.040 |
Why?
|
| Neutrophils | 1 | 2020 | 104 | 0.040 |
Why?
|
| Macrophages | 1 | 2020 | 102 | 0.040 |
Why?
|
| Phenotype | 1 | 2021 | 312 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 68 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 348 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2021 | 443 | 0.040 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2013 | 1 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2013 | 1 | 0.030 |
Why?
|
| Adenoviridae Infections | 1 | 2013 | 2 | 0.030 |
Why?
|
| Thienamycins | 1 | 2013 | 6 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 6 | 0.030 |
Why?
|
| Epirubicin | 1 | 2013 | 4 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2013 | 5 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2013 | 19 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2013 | 9 | 0.030 |
Why?
|
| Cecum | 1 | 2013 | 12 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2013 | 41 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 25 | 0.030 |
Why?
|
| DNA Damage | 1 | 2013 | 29 | 0.030 |
Why?
|
| Shock, Septic | 1 | 2013 | 60 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 66 | 0.030 |
Why?
|
| Inflammation | 1 | 2013 | 272 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2020 | 3538 | 0.020 |
Why?
|
| Humans | 2 | 2022 | 27072 | 0.020 |
Why?
|
| Male | 1 | 2020 | 14772 | 0.010 |
Why?
|
| Female | 1 | 2020 | 15212 | 0.010 |
Why?
|